{"id":962001,"date":"2026-05-13T07:05:22","date_gmt":"2026-05-13T11:05:22","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/pds-biotech-reports-first-quarter-2026-financial-results-and-provides-clinical-programs-and-corporate-update\/"},"modified":"2026-05-13T07:05:22","modified_gmt":"2026-05-13T11:05:22","slug":"pds-biotech-reports-first-quarter-2026-financial-results-and-provides-clinical-programs-and-corporate-update","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/pds-biotech-reports-first-quarter-2026-financial-results-and-provides-clinical-programs-and-corporate-update\/","title":{"rendered":"PDS Biotech Reports First Quarter 2026 Financial Results and Provides Clinical Programs and Corporate Update"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"center\">\n        <em>Investor Webcast Scheduled for 8:00 am ET<\/em>\n      <\/p>\n<p>PRINCETON, N.J., May  13, 2026  (GLOBE NEWSWIRE) &#8212; PDS Biotechnology Corporation (Nasdaq: PDSB) (\u201cPDS Biotech\u201d or the \u201cCompany\u201d), a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers, today provided a business and clinical programs update and reported financial results for the quarter ended March 31, 2026.<\/p>\n<p>\u201cDuring the first quarter, we made meaningful clinical and regulatory progress across our clinical pipeline,\u201d said Frank Bedu-Addo, PhD, President and CEO of PDS Biotech. \u201cWe work towards restarting enrollment in the amended VERSATILE-003 Phase 3 trial. With regards to PDS01ADC, we have completed enrollment in the metastatic colorectal cancer trial, and the advanced castration resistant prostate cancer trial continues to recruit well\u201d.<\/p>\n<p>Dr. Bedu-Addo continued: \u201cWe believe the progress achieved during the quarter reflects the continued advancement and maturation of our clinical portfolio. We remain focused on advancing potentially differentiated immunotherapy candidates designed to address significant unmet medical needs for patients with difficult-to-treat cancers\u201d.<\/p>\n<p>\n        <strong>Clinical and Corporate Update<\/strong>\n      <\/p>\n<ul type=\"disc\">\n<li>\n          <strong>Amended VERSATILE-003 Phase 3 clinical trial protocol <\/strong>to incorporate progression-free survival (PFS) as an interim primary endpoint, creating a potential accelerated approval pathway for PDS0101 in HPV16-positive recurrent and\/or metastatic head and neck cancer. Median overall survival remains the primary endpoint for full FDA approval. The amendment also reduces the number of enrolled patients while maintaining statistical power. Patients already enrolled prior to the amendment remain on the trial and continue to receive treatment.<\/p>\n<\/li>\n<li>\n          <strong>Announced publication of positive clinical and immunological biomarker data from Stage 1 of NCI-led Metastatic Colorectal Cancer (mCRC) trial evaluating PDS01ADC, the Company\u2019s tumor-targeted IL-12 immunocytokine. <\/strong>The results, published in the March issue of <em>Journal of Clinical Oncology (JCO) Oncology Advances<\/em>, included:<\/p>\n<ul type=\"circle\">\n<li>Objective response rate (ORR) by RECIST v1.1: 77.8% (7\/9) at six months; in the parallel trial without PDS01ADC, the ORR was 35% (7\/20)<\/li>\n<li>24-month survival rate approximately 85%; in the parallel trial without PDS01ADC, the 24-month survival rate was approximately 40%<\/li>\n<li>Extrahepatic progression-free survival (PFS): median not reached at minimum follow-up of 13.1 months; in the parallel trial without PDS01ADC, the PFS was 8.1 months\n<\/li>\n<\/ul>\n<\/li>\n<li>\n          <strong>Presented encouraging early results from an NCI-led trial investigating PDS01ADC <\/strong>at the AACR special conference on prostate cancer research. In patients with metastatic castration-resistant prostate cancer (mCRPC) the majority of whom received third-line treatment options \u2014 the combination of PDS01ADC and docetaxel demonstrated encouraging median PFS of 9.6 months and a median PSA decline of 40%, with 6 of 16 patients achieving greater than 50% decline.<\/p>\n<\/li>\n<li>\n          <strong>Strengthened the intellectual property estate for PDS0101<\/strong> with new patents granted in the U.S. and Japan. The new U.S. patent, combined with anticipated biologics exclusivity, extends market protection into the 2040s. The Japanese patent adds broad composition of matter claims to existing protections across major markets.<\/li>\n<\/ul>\n<p>\n        <strong>First Quarter 2026 Financial Results<\/strong>\n      <\/p>\n<p>Reported net loss for the quarter ended March 31, 2026, was approximately $7.3 million, or $0.13 per basic and diluted share, compared to a net loss of $8.5 million, or $0.21 per basic and diluted share for the quarter ended March 31, 2025.<\/p>\n<p>Research and development expenses for the quarter ended March 31, 2026, were $3.5 million, compared to $5.8 million for the quarter ended March 31, 2025. The decrease was primarily due to lower clinical and manufacturing costs.<\/p>\n<p>General and administrative expenses for the year ended March 31, 2026, were $3.1 million, compared to $3.3 million for the year ended March 31, 2025. The decrease was primarily due to lower professional fees.<\/p>\n<p>Total operating expenses for the year ended March 31, 2026, were $6.5 million compared to $9.1 million for the quarter ended March 31, 2025.<\/p>\n<p>Net interest expense was $0.8 million for the quarter ended March 31, 2026, compared to $0.6 million for the quarter ended March 31, 2025.<\/p>\n<p>The Company\u2019s cash balance as of March 31, 2026, was $21.7 million.<\/p>\n<p>\n        <strong>Conference Call Details<\/strong>\n      <\/p>\n<ul type=\"disc\">\n<li>Date: May 13, 2026<\/li>\n<li>Time: 8:00 a.m. Eastern Time<\/li>\n<li>Dial-in: 1-877-704-4453 (Domestic) or 1-201-389-0920 (International)<\/li>\n<li>Conference I.D.: 13760368<\/li>\n<li>Webcast: <a href=\"https:\/\/viavid.webcasts.com\/starthere.jsp?ei=1761437&amp;tp_key=6d561d3af2\" rel=\"nofollow\" target=\"_blank\">Click Here<\/a><\/li>\n<li>CallMe<sup>TM<\/sup>: <a href=\"https:\/\/callme.viavid.com\/viavid\/?$Y2FsbG1lPXRydWUmcGFzc2NvZGU9MTM3NDgyNzkmaD10cnVlJmluZm89Y29tcGFueS1lbWFpbCZyPXRydWUmQj02\" rel=\"nofollow\" target=\"_blank\">Click Here<\/a> (available 15 minutes prior to the call)<\/li>\n<\/ul>\n<p>After the live webcast, the event will be archived on PDS Biotech\u2019s website for six months.<\/p>\n<p>\n        <strong>About PDS Biotechnology<\/strong>\n      <\/p>\n<p align=\"justify\">PDS Biotechnology is a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers. The Company has initiated a pivotal clinical trial to advance its lead program in advanced HPV16-positive head and neck squamous cell cancers. PDS Biotech\u2019s lead investigational targeted immunotherapy PDS0101 is being developed in combination with a standard-of-care immune checkpoint inhibitor, and also in a triple combination including PDS01ADC, an IL-12 fused antibody drug conjugate (ADC), and a standard-of-care immune checkpoint inhibitor. PDS01ADC is being evaluated in multiple phase 2 trials in various cancer indications in combination with standard of care.<\/p>\n<p>For more information, please visit <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=Uml4VliXsYl96fyDdmHqFV5S9DZL2mD8780FXzb3v9lvOMPbo_s2RSiXx3Z-MoL18UzKuea0So_DpjnliBhmc8q9gQEZHxYKP_YSeBU9kjE=\" rel=\"nofollow\" target=\"_blank\">www.pdsbiotech.com<\/a><\/p>\n<p>\n        <strong>Forward Looking Statements<\/strong>\n      <\/p>\n<p align=\"justify\">This communication contains forward-looking statements (including within the meaning of Section 21E of the United States Securities Exchange Act of 1934, as amended, and Section 27A of the United States Securities Act of 1933, as amended) concerning PDS Biotechnology Corporation (the \u201cCompany\u201d) and other matters. These statements may discuss goals, intentions and expectations as to future plans, trends, events, results of operations or financial condition, or otherwise, based on current beliefs of the Company\u2019s management, as well as assumptions made by, and information currently available to, management. Forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words such as \u201cmay,\u201d \u201cwill,\u201d \u201cshould,\u201d \u201cwould,\u201d \u201cexpect,\u201d \u201canticipate,\u201d \u201cplan,\u201d \u201clikely,\u201d \u201cbelieve,\u201d \u201cestimate,\u201d \u201cproject,\u201d \u201cintend,\u201d \u201cforecast,\u201d \u201cguidance\u201d, \u201coutlook\u201d and other similar expressions among others. Forward-looking statements are based on current beliefs and assumptions that are subject to risks and uncertainties and are not guarantees of future performance. Actual results could differ materially from those contained in any forward-looking statement as a result of various factors, including, without limitation: the Company\u2019s ability to protect its intellectual property rights; the Company\u2019s anticipated capital requirements, including the Company\u2019s anticipated cash runway and the Company\u2019s current expectations regarding its plans for future equity financings; the Company\u2019s dependence on additional financing to fund its operations and complete the development and commercialization of its product candidates, and the risks that raising such additional capital may restrict the Company\u2019s operations or require the Company to relinquish rights to the Company\u2019s technologies or product candidates; the Company\u2019s limited operating history in the Company\u2019s current line of business, which makes it difficult to evaluate the Company\u2019s prospects, the Company\u2019s business plan or the likelihood of the Company\u2019s successful implementation of such business plan; the timing for the Company or its partners to conduct clinical trials for PDS0101 (Versamune<sup>\u00ae<\/sup>\u00a0HPV), PDS01ADC, PDS0103 (Versamune<sup>\u00ae<\/sup>\u00a0MUC1) and other Versamune\u00ae based product candidates; the future success of such trials; the successful implementation of the Company\u2019s research and development programs and collaborations, including any collaboration studies concerning PDS0101, PDS01ADC, PDS0103 and other Versamune<sup>\u00ae<\/sup> based product candidates and the Company\u2019s interpretation of the results and findings of such programs and collaborations and whether such results are sufficient to support the future success of the Company\u2019s product candidates; the success, timing and cost of the Company\u2019s or its partners\u2019 ongoing clinical trials and anticipated clinical trials for the Company\u2019s current product candidates, including statements regarding response rates, the timing of initiation, pace of enrollment and completion of the trials (including the Company\u2019s ability to fully fund its disclosed clinical trials, which assumes no material changes to the Company\u2019s currently projected expenses), futility analyses, presentations at conferences and data reported in an abstract, and receipt of interim or preliminary results (including, without limitation, any preclinical results or data), which are not necessarily indicative of the final results of the Company\u2019s ongoing clinical trials; any Company statements about its understanding of product candidates mechanisms of action and interpretation of preclinical and early clinical results from its clinical development programs and any collaboration studies; the Company\u2019s ability to continue as a going concern; and other factors, including legislative, regulatory, political and economic developments not within the Company\u2019s control. The foregoing review of important factors that could cause actual events to differ from expectations should not be construed as exhaustive and should be read in conjunction with statements that are included herein and elsewhere, including the other risks, uncertainties, and other factors described under \u201cRisk Factors,\u201d \u201cManagement\u2019s Discussion and Analysis of Financial Condition and Results of Operations\u201d and elsewhere in the documents we file with the U.S. Securities and Exchange Commission. The forward-looking statements are made only as of the date of this press release and, except as required by applicable law, the Company undertakes no obligation to revise or update any forward-looking statement, or to make any other forward-looking statements, whether as a result of new information, future events or otherwise.\u202f\u202f<\/p>\n<p align=\"justify\">Versamune<sup>\u00ae<\/sup> is a registered trademark of PDS Biotechnology Corporation.<\/p>\n<p>\n        <strong>Investor Contact:<\/strong><br \/>\n        <br \/>Mike Moyer<br \/>LifeSci Advisors<br \/>Phone +1 (617) 308-4306 <br \/>Email: <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=6Hqj_FqTjwxSOIDaG1zswaGDeTI8pTmsCMb7uIx1eYCQH_1Nyz-DjcaHhbluRoPFDyJwHUcwyNB_QleS0rklWzCdT6f6jMHIjFLuWe-HgVxPTuTRpIzRnYu_kvN-ac5j\" rel=\"nofollow\" target=\"_blank\">mmoyer@lifesciadvisors.com<\/a><\/p>\n<p>\n        <strong>Media Contact:<\/strong><br \/>\n        <br \/>Jude Gorman \/ Kiki Torpey<br \/>Collected Strategies<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=-iYG7jcTbxSBx6rjdfjdmlyQ6qa4KDF_0VGNNiRrPoKdqqLrjYdNawZZ56Oir2drC89B_6st9yCkE_dL1NyZDnVr2zJITnnXzdG9tYBv6LQd9k4LJYnP05fyvaFILgg-\" rel=\"nofollow\" target=\"_blank\">PDS-CS@collectedstrategies.com<\/a><\/p>\n<p align=\"center\">&#8212;tables to follow&#8212;<\/p>\n<table style=\"border-collapse: collapse;width:100.042%;border-collapse:collapse\">\n<tr>\n<td colspan=\"9\" style=\"width:100.019%;text-align: center;vertical-align: middle\">\n            <strong>PDS BIOTECHNOLOGY CORPORATION AND SUBSIDIARY<\/strong>\n          <\/td>\n<\/tr>\n<tr>\n<td colspan=\"9\" style=\"width:100.019%;text-align: center;vertical-align: middle\">\n            <strong>Selected Balance Sheet Data<\/strong>\n          <\/td>\n<\/tr>\n<tr>\n<td colspan=\"9\" style=\"width:100.019%;text-align: center;vertical-align: middle\">\n            <strong>(Unaudited)<\/strong>\n          <\/td>\n<\/tr>\n<tr>\n<td style=\"width:69.7156%;text-align: right;vertical-align: middle\">\u00a0<\/td>\n<td style=\"width:1.05099%;text-align: right;vertical-align: middle\">\u00a0<\/td>\n<td colspan=\"3\" style=\"width:14.1008%\">\u00a0<\/td>\n<td style=\"width:1.05099%\">\u00a0<\/td>\n<td colspan=\"3\" style=\"width:14.1008%\">\u00a0<\/td>\n<\/tr>\n<tr>\n<td rowspan=\"2\" style=\"width:69.7156%;text-align: right;vertical-align: middle\">\u00a0<\/td>\n<td style=\"width:1.05099%;text-align: right;vertical-align: middle\">\u00a0<\/td>\n<td colspan=\"3\" style=\"width:14.1008%;text-align: center;vertical-align: middle\">\n            <strong>March 31,<\/strong>\n          <\/td>\n<td style=\"width:1.05099%;text-align: center;vertical-align: middle\">\u00a0<\/td>\n<td colspan=\"3\" style=\"width:14.1008%;text-align: center;vertical-align: middle\">\n            <strong>December 31,<\/strong>\n          <\/td>\n<\/tr>\n<tr>\n<td style=\"width:1.05099%;text-align: right;vertical-align: middle\">\u00a0<\/td>\n<td colspan=\"3\" style=\"width:14.1008%;border-bottom: solid black 1pt;padding-right: 0;text-align: center;vertical-align: middle\">\n            <strong>2026<\/strong><br \/>\n            \n          <\/td>\n<td style=\"width:1.05099%;text-align: center;vertical-align: middle\">\u00a0<\/td>\n<td colspan=\"3\" style=\"width:14.1008%;border-bottom: solid black 1pt;padding-right: 0;text-align: center;vertical-align: middle\">\n            <strong>2025<\/strong><br \/>\n            \n          <\/td>\n<\/tr>\n<tr>\n<td style=\"max-width:69%;width:69.7156%;min-width:69%;text-align: left;vertical-align: middle\">Cash and cash equivalents<\/td>\n<td style=\"max-width:1%;width:1.05099%;min-width:1%;text-align: right;vertical-align: middle\">\u00a0<\/td>\n<td style=\"max-width:2%;width:2.01439%;min-width:2%;border-top: solid black 1pt;padding-right: 0;text-align: right;vertical-align: middle\">$<\/td>\n<td style=\"max-width:10%;width:10.072%;min-width:10%;border-top: solid black 1pt;padding-left: 0;padding-right: 0;text-align: right;vertical-align: middle\">21,660,496<\/td>\n<td style=\"max-width:2%;width:2.01439%;min-width:2%;border-top: solid black 1pt;padding-left: 0;text-align: left;vertical-align: middle\">\u00a0<\/td>\n<td style=\"max-width:1%;width:1.05099%;min-width:1%;text-align: left;vertical-align: middle\">\u00a0<\/td>\n<td style=\"max-width:2%;width:2.01439%;min-width:2%;border-top: solid black 1pt;padding-right: 0;text-align: right;vertical-align: middle\">$<\/td>\n<td style=\"max-width:10%;width:10.072%;min-width:10%;border-top: solid black 1pt;padding-left: 0;padding-right: 0;text-align: right;vertical-align: middle\">26,711,969<\/td>\n<td style=\"max-width:2%;width:2.01439%;min-width:2%;border-top: solid black 1pt;padding-left: 0;text-align: left;vertical-align: middle\">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"width:69.7156%;text-align: left;vertical-align: middle\">Working capital<\/td>\n<td style=\"width:1.05099%;text-align: right;vertical-align: middle\">\u00a0<\/td>\n<td style=\"width:2.01439%;padding-right: 0;text-align: right;vertical-align: middle\">$<\/td>\n<td style=\"width:10.072%;padding-left: 0;padding-right: 0;text-align: right;vertical-align: middle\">12,739,152<\/td>\n<td style=\"width:2.01439%;padding-left: 0;text-align: left;vertical-align: middle\">\u00a0<\/td>\n<td style=\"width:1.05099%;text-align: left;vertical-align: middle\">\u00a0<\/td>\n<td style=\"width:2.01439%;padding-right: 0;text-align: right;vertical-align: middle\">$<\/td>\n<td style=\"width:10.072%;padding-left: 0;padding-right: 0;text-align: right;vertical-align: middle\">18,770,871<\/td>\n<td style=\"width:2.01439%;padding-left: 0;text-align: left;vertical-align: middle\">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"width:69.7156%;text-align: left;vertical-align: middle\">Total assets<\/td>\n<td style=\"width:1.05099%;text-align: right;vertical-align: middle\">\u00a0<\/td>\n<td style=\"width:2.01439%;padding-right: 0;text-align: right;vertical-align: middle\">$<\/td>\n<td style=\"width:10.072%;padding-left: 0;padding-right: 0;text-align: right;vertical-align: middle\">24,663,026<\/td>\n<td style=\"width:2.01439%;padding-left: 0;text-align: left;vertical-align: middle\">\u00a0<\/td>\n<td style=\"width:1.05099%;text-align: left;vertical-align: middle\">\u00a0<\/td>\n<td style=\"width:2.01439%;padding-right: 0;text-align: right;vertical-align: middle\">$<\/td>\n<td style=\"width:10.072%;padding-left: 0;padding-right: 0;text-align: right;vertical-align: middle\">30,494,083<\/td>\n<td style=\"width:2.01439%;padding-left: 0;text-align: left;vertical-align: middle\">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"width:69.7156%;text-align: left;vertical-align: middle\">Long term debt<\/td>\n<td style=\"width:1.05099%;text-align: right;vertical-align: middle\">\u00a0<\/td>\n<td style=\"width:2.01439%;padding-right: 0;text-align: right;vertical-align: middle\">$<\/td>\n<td style=\"width:10.072%;padding-left: 0;padding-right: 0;text-align: right;vertical-align: middle\">10,605,985<\/td>\n<td style=\"width:2.01439%;padding-left: 0;text-align: left;vertical-align: middle\">\u00a0<\/td>\n<td style=\"width:1.05099%;text-align: left;vertical-align: middle\">\u00a0<\/td>\n<td style=\"width:2.01439%;padding-right: 0;text-align: right;vertical-align: middle\">$<\/td>\n<td style=\"width:10.072%;padding-left: 0;padding-right: 0;text-align: right;vertical-align: middle\">11,733,350<\/td>\n<td style=\"width:2.01439%;padding-left: 0;text-align: left;vertical-align: middle\">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"width:69.7156%;text-align: left;vertical-align: middle\">Accumulated deficit<\/td>\n<td style=\"width:1.05099%;text-align: right;vertical-align: middle\">\u00a0<\/td>\n<td style=\"width:2.01439%;padding-right: 0;text-align: right;vertical-align: middle\">$<\/td>\n<td style=\"width:10.072%;padding-left: 0;padding-right: 0;text-align: right;vertical-align: middle\">(223,955,560<\/td>\n<td style=\"width:2.01439%;padding-left: 0;text-align: left;vertical-align: middle\">)<\/td>\n<td style=\"width:1.05099%;text-align: left;vertical-align: middle\">\u00a0<\/td>\n<td style=\"width:2.01439%;padding-right: 0;text-align: right;vertical-align: middle\">$<\/td>\n<td style=\"width:10.072%;padding-left: 0;padding-right: 0;text-align: right;vertical-align: middle\">(216,606,504<\/td>\n<td style=\"width:2.01439%;padding-left: 0;text-align: left;vertical-align: middle\">)<\/td>\n<\/tr>\n<tr>\n<td style=\"width:69.7156%;text-align: left;vertical-align: middle\">Total stockholders\u2019 equity<\/td>\n<td style=\"width:1.05099%;text-align: right;vertical-align: middle\">\u00a0<\/td>\n<td style=\"width:2.01439%;padding-right: 0;text-align: right;vertical-align: middle\">$<\/td>\n<td style=\"width:10.072%;padding-left: 0;padding-right: 0;text-align: right;vertical-align: middle\">3,892,643<\/td>\n<td style=\"width:2.01439%;padding-left: 0;text-align: left;vertical-align: middle\">\u00a0<\/td>\n<td style=\"width:1.05099%;text-align: left;vertical-align: middle\">\u00a0<\/td>\n<td style=\"width:2.01439%;padding-right: 0;text-align: right;vertical-align: middle\">$<\/td>\n<td style=\"width:10.072%;padding-left: 0;padding-right: 0;text-align: right;vertical-align: middle\">9,251,833<\/td>\n<td style=\"width:2.01439%;padding-left: 0;text-align: left;vertical-align: middle\">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"width:69.7156%\">\u00a0<\/td>\n<td style=\"width:1.05099%\">\u00a0<\/td>\n<td colspan=\"3\" style=\"width:14.1008%\">\u00a0<\/td>\n<td style=\"width:1.05099%\">\u00a0<\/td>\n<td colspan=\"3\" style=\"width:14.1008%\">\u00a0<\/td>\n<\/tr>\n<\/table>\n<table style=\"border-collapse: collapse;width:100.042%;border-collapse:collapse\">\n<tr>\n<td colspan=\"9\" style=\"width:99.9775%;text-align: center;vertical-align: middle\">\n            <strong>PDS BIOTECHNOLOGY CORPORATION AND SUBSIDIARY <br \/>Condensed Consolidated Statements of Operations and Comprehensive Loss<br \/><\/strong><br \/>\n            <strong>(Unaudited)<\/strong>\n          <\/td>\n<\/tr>\n<tr>\n<td style=\"width:70.0368%\">\u00a0<\/td>\n<td style=\"width:0.963006%\">\u00a0<\/td>\n<td colspan=\"7\">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"width:70.0368%\">\u00a0<\/td>\n<td style=\"width:0.963006%\">\u00a0<\/td>\n<td colspan=\"7\" style=\"width:28.9777%;text-align: center;vertical-align: middle\">\n            <strong>Three Months Ended Mar 31,\u00a0<\/strong>\n          <\/td>\n<\/tr>\n<tr>\n<td style=\"width:70.0368%\">\u00a0<\/td>\n<td style=\"width:0.963006%\">\u00a0<\/td>\n<td colspan=\"3\" style=\"width:14.0074%;text-align: center;vertical-align: middle\">\n            <strong>2026<\/strong>\n          <\/td>\n<td style=\"width:0.963006%\">\u00a0<\/td>\n<td colspan=\"3\" style=\"width:14.0074%;text-align: center;vertical-align: middle\">\n            <strong>2025<\/strong>\n          <\/td>\n<\/tr>\n<tr>\n<td style=\"width:70.0368%;text-align: left;vertical-align: middle\">Operating expenses:<\/td>\n<td style=\"width:0.963006%;text-align: left;vertical-align: middle\">\u00a0<\/td>\n<td colspan=\"3\" style=\"width:14.0074%;border-top: solid black 1pt;text-align: right;vertical-align: middle\">\u00a0<\/td>\n<td style=\"width:0.963006%;text-align: right;vertical-align: middle\">\u00a0<\/td>\n<td colspan=\"3\" style=\"width:14.0074%;border-top: solid black 1pt;text-align: right;vertical-align: middle\">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"max-width:70%;width:70.0368%;min-width:70%;text-align: left;vertical-align: middle\">\u00a0\u00a0Research and development expenses<\/td>\n<td style=\"max-width:1%;width:0.963006%;min-width:1%;text-align: left;vertical-align: middle\">\u00a0<\/td>\n<td style=\"max-width:2%;width:2.01356%;min-width:2%;padding-right: 0;text-align: right;vertical-align: middle\">$<\/td>\n<td style=\"max-width:10%;width:9.98024%;min-width:10%;padding-left: 0;padding-right: 0;text-align: right;vertical-align: middle\">3,457,032<\/td>\n<td style=\"max-width:2%;width:2.01356%;min-width:2%;padding-left: 0;text-align: left;vertical-align: middle\">\u00a0<\/td>\n<td style=\"max-width:1%;width:0.963006%;min-width:1%;text-align: right;vertical-align: middle\">\u00a0<\/td>\n<td style=\"max-width:2%;width:2.01356%;min-width:2%;padding-right: 0;text-align: right;vertical-align: middle\">$<\/td>\n<td style=\"max-width:10%;width:9.98024%;min-width:10%;padding-left: 0;padding-right: 0;text-align: right;vertical-align: middle\">5,830,999<\/td>\n<td style=\"max-width:2%;width:2.01356%;min-width:2%;padding-left: 0;text-align: left;vertical-align: middle\">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"width:70.0368%;text-align: left;vertical-align: middle\">\u00a0\u00a0General and administrative expenses<\/td>\n<td style=\"width:0.963006%;text-align: left;vertical-align: middle\">\u00a0<\/td>\n<td style=\"width:2.01356%;border-bottom: solid black 1pt;padding-right: 0;text-align: right;vertical-align: middle\">\u00a0<\/td>\n<td style=\"width:9.98024%;border-bottom: solid black 1pt;padding-left: 0;padding-right: 0;text-align: right;vertical-align: middle\">3,064,055<\/td>\n<td style=\"width:2.01356%;border-bottom: solid black 1pt;padding-left: 0;text-align: left;vertical-align: middle\">\u00a0<\/td>\n<td style=\"width:0.963006%;text-align: right;vertical-align: middle\">\u00a0<\/td>\n<td style=\"width:2.01356%;border-bottom: solid black 1pt;padding-right: 0;text-align: right;vertical-align: middle\">\u00a0<\/td>\n<td style=\"width:9.98024%;border-bottom: solid black 1pt;padding-left: 0;padding-right: 0;text-align: right;vertical-align: middle\">3,274,759<\/td>\n<td style=\"width:2.01356%;border-bottom: solid black 1pt;padding-left: 0;text-align: left;vertical-align: middle\">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"width:70.0368%;text-align: left;vertical-align: middle\">Total operating expenses<\/td>\n<td style=\"width:0.963006%;text-align: left;vertical-align: middle\">\u00a0<\/td>\n<td style=\"width:2.01356%;border-bottom: solid black 1pt;padding-right: 0;text-align: right;vertical-align: middle\">$<\/td>\n<td style=\"width:9.98024%;border-bottom: solid black 1pt;padding-left: 0;padding-right: 0;text-align: right;vertical-align: middle\">6,521,087<\/td>\n<td style=\"width:2.01356%;border-bottom: solid black 1pt;padding-left: 0;text-align: left;vertical-align: middle\">\u00a0<\/td>\n<td style=\"width:0.963006%;text-align: right;vertical-align: middle\">\u00a0<\/td>\n<td style=\"width:2.01356%;border-bottom: solid black 1pt;padding-right: 0;text-align: right;vertical-align: middle\">$<\/td>\n<td style=\"width:9.98024%;border-bottom: solid black 1pt;padding-left: 0;padding-right: 0;text-align: right;vertical-align: middle\">9,105,758<\/td>\n<td style=\"width:2.01356%;border-bottom: solid black 1pt;padding-left: 0;text-align: left;vertical-align: middle\">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"width:70.0368%;text-align: right;vertical-align: middle\">\u00a0<\/td>\n<td style=\"width:0.963006%;text-align: right;vertical-align: middle\">\u00a0<\/td>\n<td colspan=\"3\" style=\"width:14.0074%;text-align: right;vertical-align: middle\">\u00a0<\/td>\n<td style=\"width:0.963006%;text-align: right;vertical-align: middle\">\u00a0<\/td>\n<td colspan=\"3\" style=\"width:14.0074%;text-align: right;vertical-align: middle\">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"width:70.0368%;text-align: left;vertical-align: middle\">Loss from operations<\/td>\n<td style=\"width:0.963006%;text-align: left;vertical-align: middle\">\u00a0<\/td>\n<td style=\"width:2.01356%;padding-right: 0;text-align: right;vertical-align: middle\">$<\/td>\n<td style=\"width:9.98024%;padding-left: 0;padding-right: 0;text-align: right;vertical-align: middle\">(6,521,087<\/td>\n<td style=\"width:2.01356%;padding-left: 0;text-align: left;vertical-align: middle\">)<\/td>\n<td style=\"width:0.963006%;text-align: right;vertical-align: middle\">\u00a0<\/td>\n<td style=\"width:2.01356%;padding-right: 0;text-align: right;vertical-align: middle\">$<\/td>\n<td style=\"width:9.98024%;padding-left: 0;padding-right: 0;text-align: right;vertical-align: middle\">(9,105,758<\/td>\n<td style=\"width:2.01356%;padding-left: 0;text-align: left;vertical-align: middle\">)<\/td>\n<\/tr>\n<tr>\n<td style=\"width:70.0368%;text-align: right;vertical-align: middle\">\u00a0<\/td>\n<td style=\"width:0.963006%;text-align: right;vertical-align: middle\">\u00a0<\/td>\n<td colspan=\"3\" style=\"width:14.0074%;text-align: right;vertical-align: middle\">\u00a0<\/td>\n<td style=\"width:0.963006%;text-align: right;vertical-align: middle\">\u00a0<\/td>\n<td colspan=\"3\" style=\"width:14.0074%;text-align: right;vertical-align: middle\">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"width:70.0368%;text-align: left;vertical-align: middle\">Interest income (expense)<\/td>\n<td style=\"width:0.963006%;text-align: left;vertical-align: middle\">\u00a0<\/td>\n<td colspan=\"3\" style=\"width:14.0074%;text-align: right;vertical-align: middle\">\u00a0<\/td>\n<td style=\"width:0.963006%;text-align: right;vertical-align: middle\">\u00a0<\/td>\n<td colspan=\"3\" style=\"width:14.0074%;text-align: right;vertical-align: middle\">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"width:70.0368%;text-align: left;vertical-align: middle\">\u00a0\u00a0Interest income<\/td>\n<td style=\"width:0.963006%;text-align: left;vertical-align: middle\">\u00a0<\/td>\n<td style=\"width:2.01356%;padding-right: 0;text-align: right;vertical-align: middle\">$<\/td>\n<td style=\"width:9.98024%;padding-left: 0;padding-right: 0;text-align: right;vertical-align: middle\">186,814<\/td>\n<td style=\"width:2.01356%;padding-left: 0;text-align: left;vertical-align: middle\">\u00a0<\/td>\n<td style=\"width:0.963006%;text-align: right;vertical-align: middle\">\u00a0<\/td>\n<td style=\"width:2.01356%;padding-right: 0;text-align: right;vertical-align: middle\">$<\/td>\n<td style=\"width:9.98024%;padding-left: 0;padding-right: 0;text-align: right;vertical-align: middle\">377,849<\/td>\n<td style=\"width:2.01356%;padding-left: 0;text-align: left;vertical-align: middle\">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"width:70.0368%;text-align: left;vertical-align: middle\">\u00a0\u00a0Interest expense<\/td>\n<td style=\"width:0.963006%;text-align: left;vertical-align: middle\">\u00a0<\/td>\n<td style=\"width:2.01356%;border-bottom: solid black 1pt;padding-right: 0;text-align: right;vertical-align: middle\">\u00a0<\/td>\n<td style=\"width:9.98024%;border-bottom: solid black 1pt;padding-left: 0;padding-right: 0;text-align: right;vertical-align: middle\">(1,014,782<\/td>\n<td style=\"width:2.01356%;border-bottom: solid black 1pt;padding-left: 0;text-align: left;vertical-align: middle\">)<\/td>\n<td style=\"width:0.963006%;text-align: right;vertical-align: middle\">\u00a0<\/td>\n<td style=\"width:2.01356%;border-bottom: solid black 1pt;padding-right: 0;text-align: right;vertical-align: middle\">\u00a0<\/td>\n<td style=\"width:9.98024%;border-bottom: solid black 1pt;padding-left: 0;padding-right: 0;text-align: right;vertical-align: middle\">(930,878<\/td>\n<td style=\"width:2.01356%;border-bottom: solid black 1pt;padding-left: 0;text-align: left;vertical-align: middle\">)<\/td>\n<\/tr>\n<tr>\n<td style=\"width:70.0368%;text-align: left;vertical-align: middle\">Interest income (expense), net<\/td>\n<td style=\"width:0.963006%;text-align: left;vertical-align: middle\">\u00a0<\/td>\n<td style=\"width:2.01356%;border-bottom: solid black 1pt;padding-right: 0;text-align: right;vertical-align: middle\">$<\/td>\n<td style=\"width:9.98024%;border-bottom: solid black 1pt;padding-left: 0;padding-right: 0;text-align: right;vertical-align: middle\">(827,968<\/td>\n<td style=\"width:2.01356%;border-bottom: solid black 1pt;padding-left: 0;text-align: left;vertical-align: middle\">)<\/td>\n<td style=\"width:0.963006%;text-align: right;vertical-align: middle\">\u00a0<\/td>\n<td style=\"width:2.01356%;border-bottom: solid black 1pt;padding-right: 0;text-align: right;vertical-align: middle\">$<\/td>\n<td style=\"width:9.98024%;border-bottom: solid black 1pt;padding-left: 0;padding-right: 0;text-align: right;vertical-align: middle\">(553,028<\/td>\n<td style=\"width:2.01356%;border-bottom: solid black 1pt;padding-left: 0;text-align: left;vertical-align: middle\">)<\/td>\n<\/tr>\n<tr>\n<td style=\"width:70.0368%;text-align: right;vertical-align: middle\">\u00a0<\/td>\n<td style=\"width:0.963006%;text-align: right;vertical-align: middle\">\u00a0<\/td>\n<td colspan=\"3\" style=\"width:14.0074%;text-align: right;vertical-align: middle\">\u00a0<\/td>\n<td style=\"width:0.963006%;text-align: right;vertical-align: middle\">\u00a0<\/td>\n<td colspan=\"3\" style=\"width:14.0074%;text-align: right;vertical-align: middle\">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"width:70.0368%;text-align: left;vertical-align: middle\">Loss before income taxes<\/td>\n<td style=\"width:0.963006%;text-align: left;vertical-align: middle\">\u00a0<\/td>\n<td style=\"width:2.01356%;padding-right: 0;text-align: right;vertical-align: middle\">$<\/td>\n<td style=\"width:9.98024%;padding-left: 0;padding-right: 0;text-align: right;vertical-align: middle\">(7,349,055<\/td>\n<td style=\"width:2.01356%;padding-left: 0;text-align: left;vertical-align: middle\">)<\/td>\n<td style=\"width:0.963006%;text-align: right;vertical-align: middle\">\u00a0<\/td>\n<td style=\"width:2.01356%;padding-right: 0;text-align: right;vertical-align: middle\">$<\/td>\n<td style=\"width:9.98024%;padding-left: 0;padding-right: 0;text-align: right;vertical-align: middle\">(9,658,786<\/td>\n<td style=\"width:2.01356%;padding-left: 0;text-align: left;vertical-align: middle\">)<\/td>\n<\/tr>\n<tr>\n<td style=\"width:70.0368%;text-align: left;vertical-align: middle\">Benefit from income taxes<\/td>\n<td style=\"width:0.963006%;text-align: right;vertical-align: middle\">\u00a0<\/td>\n<td style=\"width:2.01356%;border-bottom: solid black 1pt;padding-right: 0;text-align: right;vertical-align: middle\">\u00a0<\/td>\n<td style=\"width:9.98024%;border-bottom: solid black 1pt;padding-left: 0;padding-right: 0;text-align: right;vertical-align: middle\">&#8211;<\/td>\n<td style=\"width:2.01356%;border-bottom: solid black 1pt;padding-left: 0;text-align: left;vertical-align: middle\">\u00a0<\/td>\n<td style=\"width:0.963006%;text-align: right;vertical-align: middle\">\u00a0<\/td>\n<td style=\"width:2.01356%;border-bottom: solid black 1pt;padding-right: 0;text-align: right;vertical-align: middle\">\u00a0<\/td>\n<td style=\"width:9.98024%;border-bottom: solid black 1pt;padding-left: 0;padding-right: 0;text-align: right;vertical-align: middle\">1,169,820<\/td>\n<td style=\"width:2.01356%;border-bottom: solid black 1pt;padding-left: 0;text-align: left;vertical-align: middle\">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"width:70.0368%;text-align: left;vertical-align: middle\">Net loss and comprehensive loss<\/td>\n<td style=\"width:0.963006%;text-align: left;vertical-align: middle\">\u00a0<\/td>\n<td style=\"width:2.01356%;border-top: solid black 1pt;border-bottom: double black 3pt;padding-right: 0;text-align: right;vertical-align: middle\">$<\/td>\n<td style=\"width:9.98024%;border-top: solid black 1pt;border-bottom: double black 3pt;padding-left: 0;padding-right: 0;text-align: right;vertical-align: middle\">(7,349,055<\/td>\n<td style=\"width:2.01356%;border-top: solid black 1pt;border-bottom: double black 3pt;padding-left: 0;text-align: left;vertical-align: middle\">)<\/td>\n<td style=\"width:0.963006%;text-align: right;vertical-align: middle\">\u00a0<\/td>\n<td style=\"width:2.01356%;border-top: solid black 1pt;border-bottom: double black 3pt;padding-right: 0;text-align: right;vertical-align: middle\">$<\/td>\n<td style=\"width:9.98024%;border-top: solid black 1pt;border-bottom: double black 3pt;padding-left: 0;padding-right: 0;text-align: right;vertical-align: middle\">(8,488,966<\/td>\n<td style=\"width:2.01356%;border-top: solid black 1pt;border-bottom: double black 3pt;padding-left: 0;text-align: left;vertical-align: middle\">)<\/td>\n<\/tr>\n<tr>\n<td style=\"width:70.0368%;text-align: right;vertical-align: middle\">\u00a0<\/td>\n<td style=\"width:0.963006%;text-align: right;vertical-align: middle\">\u00a0<\/td>\n<td colspan=\"3\" style=\"width:14.0074%;text-align: right;vertical-align: middle\">\u00a0<\/td>\n<td style=\"width:0.963006%;text-align: right;vertical-align: middle\">\u00a0<\/td>\n<td colspan=\"3\" style=\"width:14.0074%;text-align: right;vertical-align: middle\">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"width:70.0368%;text-align: left;vertical-align: middle\">Per share information:<\/td>\n<td style=\"width:0.963006%;text-align: left;vertical-align: middle\">\u00a0<\/td>\n<td colspan=\"3\" style=\"width:14.0074%;text-align: right;vertical-align: middle\">\u00a0<\/td>\n<td style=\"width:0.963006%;text-align: right;vertical-align: middle\">\u00a0<\/td>\n<td colspan=\"3\" style=\"width:14.0074%;text-align: right;vertical-align: middle\">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"width:70.0368%;text-align: left;vertical-align: middle\">Net loss per share, basic and diluted<\/td>\n<td style=\"width:0.963006%;text-align: left;vertical-align: middle\">\u00a0<\/td>\n<td style=\"width:2.01356%;border-bottom: double black 3pt;padding-right: 0;text-align: right;vertical-align: middle\">$<\/td>\n<td style=\"width:9.98024%;border-bottom: double black 3pt;padding-left: 0;padding-right: 0;text-align: right;vertical-align: middle\">(0.13<\/td>\n<td style=\"width:2.01356%;border-bottom: double black 3pt;padding-left: 0;text-align: left;vertical-align: middle\">)<\/td>\n<td style=\"width:0.963006%;text-align: right;vertical-align: middle\">\u00a0<\/td>\n<td style=\"width:2.01356%;border-bottom: double black 3pt;padding-right: 0;text-align: right;vertical-align: middle\">$<\/td>\n<td style=\"width:9.98024%;border-bottom: double black 3pt;padding-left: 0;padding-right: 0;text-align: right;vertical-align: middle\">(0.21<\/td>\n<td style=\"width:2.01356%;border-bottom: double black 3pt;padding-left: 0;text-align: left;vertical-align: middle\">)<\/td>\n<\/tr>\n<tr>\n<td style=\"width:70.0368%;text-align: left;vertical-align: middle\">Weighted average common shares outstanding basic and diluted<\/td>\n<td style=\"width:0.963006%;text-align: left;vertical-align: middle\">\u00a0<\/td>\n<td style=\"width:2.01356%;border-bottom: double black 3pt;padding-right: 0;text-align: right;vertical-align: middle\">\u00a0<\/td>\n<td style=\"width:9.98024%;border-bottom: double black 3pt;padding-left: 0;padding-right: 0;text-align: right;vertical-align: middle\">55,496,279<\/td>\n<td style=\"width:2.01356%;border-bottom: double black 3pt;padding-left: 0;text-align: left;vertical-align: middle\">\u00a0<\/td>\n<td style=\"width:0.963006%\">\u00a0<\/td>\n<td style=\"width:2.01356%;border-bottom: double black 3pt;padding-right: 0;text-align: right;vertical-align: middle\">\u00a0<\/td>\n<td style=\"width:9.98024%;border-bottom: double black 3pt;padding-left: 0;padding-right: 0;text-align: right;vertical-align: middle\">40,521,001<\/td>\n<td style=\"width:2.01356%;border-bottom: double black 3pt;padding-left: 0;text-align: left;vertical-align: middle\">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"width:70.0368%\">\u00a0<\/td>\n<td style=\"width:0.963006%\">\u00a0<\/td>\n<td colspan=\"3\" style=\"width:14.0074%\">\u00a0<\/td>\n<td style=\"width:0.963006%\">\u00a0<\/td>\n<td colspan=\"3\" style=\"width:14.0074%\">\u00a0<\/td>\n<\/tr>\n<\/table>\n<p align=\"center\">\n        \n      <\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTcxODY0OCM3NTk4OTQ4IzIwMTcxODg=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/NWU4MGUxNzEtNWUyZC00NmFjLWFkZDQtYTVlNzFhZGJiYTcwLTEwMjg3NjEtMjAyNi0wNS0xMy1lbg==\/tiny\/PDS-Biotechnology-Corporation.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Investor Webcast Scheduled for 8:00 am ET PRINCETON, N.J., May 13, 2026 (GLOBE NEWSWIRE) &#8212; PDS Biotechnology Corporation (Nasdaq: PDSB) (\u201cPDS Biotech\u201d or the \u201cCompany\u201d), a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers, today provided a business and clinical programs update and reported financial results for the quarter ended March 31, 2026. \u201cDuring the first quarter, we made meaningful clinical and regulatory progress across our clinical pipeline,\u201d said Frank Bedu-Addo, PhD, President and CEO of PDS Biotech. \u201cWe work towards restarting enrollment in the amended VERSATILE-003 Phase 3 trial. With regards to PDS01ADC, we have completed enrollment in the metastatic colorectal cancer trial, and the advanced castration resistant prostate cancer trial continues to &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/pds-biotech-reports-first-quarter-2026-financial-results-and-provides-clinical-programs-and-corporate-update\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;PDS Biotech Reports First Quarter 2026 Financial Results and Provides Clinical Programs and Corporate Update&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-962001","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>PDS Biotech Reports First Quarter 2026 Financial Results and Provides Clinical Programs and Corporate Update - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/pds-biotech-reports-first-quarter-2026-financial-results-and-provides-clinical-programs-and-corporate-update\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"PDS Biotech Reports First Quarter 2026 Financial Results and Provides Clinical Programs and Corporate Update - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Investor Webcast Scheduled for 8:00 am ET PRINCETON, N.J., May 13, 2026 (GLOBE NEWSWIRE) &#8212; PDS Biotechnology Corporation (Nasdaq: PDSB) (\u201cPDS Biotech\u201d or the \u201cCompany\u201d), a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers, today provided a business and clinical programs update and reported financial results for the quarter ended March 31, 2026. \u201cDuring the first quarter, we made meaningful clinical and regulatory progress across our clinical pipeline,\u201d said Frank Bedu-Addo, PhD, President and CEO of PDS Biotech. \u201cWe work towards restarting enrollment in the amended VERSATILE-003 Phase 3 trial. With regards to PDS01ADC, we have completed enrollment in the metastatic colorectal cancer trial, and the advanced castration resistant prostate cancer trial continues to &hellip; Continue reading &quot;PDS Biotech Reports First Quarter 2026 Financial Results and Provides Clinical Programs and Corporate Update&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/pds-biotech-reports-first-quarter-2026-financial-results-and-provides-clinical-programs-and-corporate-update\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-05-13T11:05:22+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTcxODY0OCM3NTk4OTQ4IzIwMTcxODg=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"8 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pds-biotech-reports-first-quarter-2026-financial-results-and-provides-clinical-programs-and-corporate-update\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pds-biotech-reports-first-quarter-2026-financial-results-and-provides-clinical-programs-and-corporate-update\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"PDS Biotech Reports First Quarter 2026 Financial Results and Provides Clinical Programs and Corporate Update\",\"datePublished\":\"2026-05-13T11:05:22+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pds-biotech-reports-first-quarter-2026-financial-results-and-provides-clinical-programs-and-corporate-update\\\/\"},\"wordCount\":1599,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pds-biotech-reports-first-quarter-2026-financial-results-and-provides-clinical-programs-and-corporate-update\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTcxODY0OCM3NTk4OTQ4IzIwMTcxODg=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pds-biotech-reports-first-quarter-2026-financial-results-and-provides-clinical-programs-and-corporate-update\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pds-biotech-reports-first-quarter-2026-financial-results-and-provides-clinical-programs-and-corporate-update\\\/\",\"name\":\"PDS Biotech Reports First Quarter 2026 Financial Results and Provides Clinical Programs and Corporate Update - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pds-biotech-reports-first-quarter-2026-financial-results-and-provides-clinical-programs-and-corporate-update\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pds-biotech-reports-first-quarter-2026-financial-results-and-provides-clinical-programs-and-corporate-update\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTcxODY0OCM3NTk4OTQ4IzIwMTcxODg=\",\"datePublished\":\"2026-05-13T11:05:22+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pds-biotech-reports-first-quarter-2026-financial-results-and-provides-clinical-programs-and-corporate-update\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pds-biotech-reports-first-quarter-2026-financial-results-and-provides-clinical-programs-and-corporate-update\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pds-biotech-reports-first-quarter-2026-financial-results-and-provides-clinical-programs-and-corporate-update\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTcxODY0OCM3NTk4OTQ4IzIwMTcxODg=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTcxODY0OCM3NTk4OTQ4IzIwMTcxODg=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pds-biotech-reports-first-quarter-2026-financial-results-and-provides-clinical-programs-and-corporate-update\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"PDS Biotech Reports First Quarter 2026 Financial Results and Provides Clinical Programs and Corporate Update\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"PDS Biotech Reports First Quarter 2026 Financial Results and Provides Clinical Programs and Corporate Update - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/pds-biotech-reports-first-quarter-2026-financial-results-and-provides-clinical-programs-and-corporate-update\/","og_locale":"en_US","og_type":"article","og_title":"PDS Biotech Reports First Quarter 2026 Financial Results and Provides Clinical Programs and Corporate Update - Market Newsdesk","og_description":"Investor Webcast Scheduled for 8:00 am ET PRINCETON, N.J., May 13, 2026 (GLOBE NEWSWIRE) &#8212; PDS Biotechnology Corporation (Nasdaq: PDSB) (\u201cPDS Biotech\u201d or the \u201cCompany\u201d), a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers, today provided a business and clinical programs update and reported financial results for the quarter ended March 31, 2026. \u201cDuring the first quarter, we made meaningful clinical and regulatory progress across our clinical pipeline,\u201d said Frank Bedu-Addo, PhD, President and CEO of PDS Biotech. \u201cWe work towards restarting enrollment in the amended VERSATILE-003 Phase 3 trial. With regards to PDS01ADC, we have completed enrollment in the metastatic colorectal cancer trial, and the advanced castration resistant prostate cancer trial continues to &hellip; Continue reading \"PDS Biotech Reports First Quarter 2026 Financial Results and Provides Clinical Programs and Corporate Update\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/pds-biotech-reports-first-quarter-2026-financial-results-and-provides-clinical-programs-and-corporate-update\/","og_site_name":"Market Newsdesk","article_published_time":"2026-05-13T11:05:22+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTcxODY0OCM3NTk4OTQ4IzIwMTcxODg=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"8 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pds-biotech-reports-first-quarter-2026-financial-results-and-provides-clinical-programs-and-corporate-update\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pds-biotech-reports-first-quarter-2026-financial-results-and-provides-clinical-programs-and-corporate-update\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"PDS Biotech Reports First Quarter 2026 Financial Results and Provides Clinical Programs and Corporate Update","datePublished":"2026-05-13T11:05:22+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pds-biotech-reports-first-quarter-2026-financial-results-and-provides-clinical-programs-and-corporate-update\/"},"wordCount":1599,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pds-biotech-reports-first-quarter-2026-financial-results-and-provides-clinical-programs-and-corporate-update\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTcxODY0OCM3NTk4OTQ4IzIwMTcxODg=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pds-biotech-reports-first-quarter-2026-financial-results-and-provides-clinical-programs-and-corporate-update\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/pds-biotech-reports-first-quarter-2026-financial-results-and-provides-clinical-programs-and-corporate-update\/","name":"PDS Biotech Reports First Quarter 2026 Financial Results and Provides Clinical Programs and Corporate Update - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pds-biotech-reports-first-quarter-2026-financial-results-and-provides-clinical-programs-and-corporate-update\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pds-biotech-reports-first-quarter-2026-financial-results-and-provides-clinical-programs-and-corporate-update\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTcxODY0OCM3NTk4OTQ4IzIwMTcxODg=","datePublished":"2026-05-13T11:05:22+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pds-biotech-reports-first-quarter-2026-financial-results-and-provides-clinical-programs-and-corporate-update\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/pds-biotech-reports-first-quarter-2026-financial-results-and-provides-clinical-programs-and-corporate-update\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pds-biotech-reports-first-quarter-2026-financial-results-and-provides-clinical-programs-and-corporate-update\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTcxODY0OCM3NTk4OTQ4IzIwMTcxODg=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTcxODY0OCM3NTk4OTQ4IzIwMTcxODg="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pds-biotech-reports-first-quarter-2026-financial-results-and-provides-clinical-programs-and-corporate-update\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"PDS Biotech Reports First Quarter 2026 Financial Results and Provides Clinical Programs and Corporate Update"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/962001","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=962001"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/962001\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=962001"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=962001"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=962001"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}